Mineralocorticoid receptor blockade in chronic kidney disease

Blood Purif. 2012;33(1-3):119-24. doi: 10.1159/000334161. Epub 2012 Jan 20.


Mineralocorticoid receptor blockers (MRBs) have proven highly successful in the treatment of congestive heart failure and resistant hypertension. In contrast, their use in chronic kidney disease (CKD) has lagged due to the concern of hyperkalemia and, possibly, because of the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers consistently reduce aldosterone activity in all patients. Low-dose MRB therapy may offer additional antihypertensive and unique anti-inflammatory benefits in select CKD populations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aldosterone / therapeutic use*
  • Animals
  • Diabetes Complications / drug therapy
  • Humans
  • Hyperaldosteronism / chemically induced
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / drug therapy*
  • Kidney Failure, Chronic / metabolism
  • Kidney Failure, Chronic / pathology
  • Mineralocorticoid Receptor Antagonists*
  • Receptors, Mineralocorticoid / metabolism


  • Mineralocorticoid Receptor Antagonists
  • Receptors, Mineralocorticoid
  • Aldosterone